Citations

Clear

2429 citation(s) found for "Shah, SS".

Accuracy of annual prescription drug expenditure forecasts inAJHP
Hartke, Patricia, Vermeulen, Lee C. , Hoffman, James M. , Shah, Nilay D. , Doloresco, Fred, Suda, Katie J. , Li, Edward C., Matusiak, Linda M., Hunkler, Robert J., Schumock, Glen T., Hartke, Patricia L

Mayo Clinic

American Journal of Health-System Pharmacy | September 18, 2015 | Volume: 72 | Issue: 19 | Pages: 1642-1648

10.2146/ajhp140850 | PMID 26386105 Get It

What would be the annual cost savings if fewer screws were used in adolescent idiopathic scoliosis treatment in the US?
Larson, A. Noelle , Polly, David W. , Ackerman, Stacey J. , Ledonio, Charles Gerald T., Lonner, Baron S. , Shah, Suken A. , Emans, John B. , Richards, B. Stephens , _, _, _, _, Larson, A Noelle , Polly, David

Mayo Clinic

Journal of Neurosurgery: Spine | September 18, 2015 | Volume: 24 | Issue: 1 | Pages: 116-123

10.3171/2015.4.spine131119 | PMID 26384134 Get It

OBJECT There is substantial heterogeneity in the number of screws used per level fused in adolescent idiopathic scoliosis (AIS) surgery. Assuming equivalent clinical outcomes, the potential cost savings of using fewer pedicle screws were estimated using a medical decision model with sensitivity analysis. METHODS Descriptive analyses explored the annual costs for 5710 AIS inpatient stays using discharge data from the 2009 Kids’ Inpatient Database (Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality), which is a national all-payer inpatient database. Patients between 10 and 17 years of age were identified using the ICD-9-CM code for idiopathic scoliosis (737.30). All inpatient stays were assumed to represent 10-level fusions with pedicle screws for AIS. High screw density was defined at 1.8 screws per level fused, and the standard screw density was defined as 1.48 screws per level fused. The surgical return for screw malposition was set at $23,762. A sensitivity analysis was performed by varying the cost per screw ($600–$1000) and the rate of surgical revisions for screw malposition (0.117%–0.483% of screws; 0.8%–4.3% of patients). The reported outcomes include estimated prevented malpositioned screws (set at 5.1%), averted revision surgeries, and annual cost savings in 2009 US dollars, assuming similar clinical outcomes (rates of complications, revision) using a standard- versus high-density pattern. RESULTS The total annual costs for 5710 AIS hospital stays was $278 million ($48,900 per patient). Substituting a high for a standard screw density yields 3.2 fewer screws implanted per patient, with 932 malpositioned screws prevented and 21 to 88 revision surgeries for implant malposition averted, and a potential annual cost savings of $11 million to $20 million (4%–7% reduction in the total cost of AIS hospitalizations). CONCLUSIONS Reducing the number of screws used in scoliosis surgery could potentially decrease national AIS hospitalization costs by up to 7%, which may improve the safety and efficiency of care. However, such a screw construct must first be proven safe and effective.
The impact of obesity on oesophageal acid exposure time on and off proton pump inhibitor therapy
Shah, Sanaya, Lacy, Brian E. , DiBaise, John K. , Vela, Marcelo F. , Lacy, Brian E. , Crowell, Michael D.

Mayo Clinic

Alimentary Pharmacology & Therapeutics | September 8, 2015 | Volume: 42 | Issue: 9 | Pages: 1093-1100

10.1111/apt.13394 | PMID 26345151 Get It

SummaryBackgroundObesity is associated with increased oesophageal acid exposure time (AET) in patients with gastro‐oesophageal reflux (GER), and may decrease the effects of proton pump inhibitors (PPIs).AimTo evaluate the effects of increased body mass on the ability of PPI therapy to decrease AET in patients with reflux symptoms.MethodsAcid exposure time profiles collected from adult patients using wireless pH‐metry while on or off PPI therapy was retrospectively reviewed. Patients were separated into five body mass index (BMI) categories as defined by the World Health Organization. A multivariable logistic regression evaluated the association between abnormal AET and BMI groups while controlling for age, gender and pH capsule placement methods.ResultsThe study group comprised 968 patients with 336 (34.7%) studied on a PPI and 632 (65.3%) studied off PPI therapy. AET (total greater than 5.3%) was found more frequently in the overweight (67%) and obese classes (74–80%) compared to those who were normal weight (40%) while off acid‐suppressing medications (P < 0.001). No significant differences were found between these groups when studied on acid‐suppressing medications, and the proportion of patients with abnormal AET across BMI classes was similar regardless of taking a PPI either once or twice daily.ConclusionsThis is the largest study to report on the relationship between BMI and oesophageal acid exposure time in patients with GER on and off PPI therapy. We conclude that obesity is related to increased acid exposure time, but with no significant difference in acid exposure time among different weight‐based groups when taking a once or twice‐daily PPI.
To clamp or not to clamp? Long‐term functional outcomes for elective off‐clamp laparoscopic partial nephrectomy
Shah, Paras , George, Arvin K. , Moreira, Daniel M. , Alom, Manaf, Okhunov, Zhamshid , Salami, Simpa S. , Waingankar, Nikhil , Schwartz, Michael J. , Vira, Manish , Richstone, Lee, Kavoussi, Louis R., Salami, Simpa S

Mayo Clinic

BJU International | September 8, 2015 | Volume: 117 | Issue: 2 | Pages: 293-299

10.1111/bju.13309 | PMID 26348366 Get It

Objective To evaluate whether elective off‐clamp laparoscopic partial nephrectomy ( LPN ) affords long‐term renal functional benefit compared with the on‐clamp approach. Patients and Methods This is a retrospective review of patients who underwent elective LPN between 2006 and 2011. Patients were followed longitudinally for up to 5 years. In all, 315 patients with radiographic evidence of a solitary renal mass and normal‐appearing contralateral kidney underwent elective LPN ; 209 were performed on‐clamp vs 106 off‐clamp. One patient who required conversion from LPN to open PN was excluded from the study. Additionally, four patients in the on‐clamp cohort who underwent subsequent radical nephrectomy for local‐regional recurrence were excluded from longitudinal functional evaluation after their procedure. The primary objective was to evaluate differences in postoperative estimated glomerular filtration rate ( eGFR ) between hilar clamping groups. Subgroup analyses were performed for patients with clamp times >30 min and those with baseline renal insufficiency ( eGFR <60 mL/min/1.73m 2 ). Risk of developing worsened or new‐onset renal insufficiency was also compared. Results The mean preoperative eGFR was similar between the on‐clamp and off‐clamp cohorts (80.7 vs 84.1 mL/min/1.73m 2 , P > 0.05). Univariable and multivariable analyses did not show significant differences in postoperative eGFR between both groups among all‐comers, those with clamp times >30 min, and patients with baseline renal insufficiency. Risk of chronic kidney disease was not diminished by the off‐clamp approach with up to 5 years of follow‐up. Conclusions Progressive recovery of renal function after hilar clamping in the elective setting eclipses short‐term functional benefit achieved with off‐clamp LPN by 6 months; there was no significant difference in eGFR or the percentage incidence of chronic kidney disease between the on‐clamp and off‐clamp cohorts with up to 5 years follow‐up. As such, eliminating transient ischaemia during elective LPN does not confer clinical benefit.
Teriparatide Therapy and Reduced Postoperative Hospitalization for Postsurgical Hypoparathyroidism
Bancos, Irina , Thompson, Geoffrey B. , Richards, Melanie L., Kasperbauer, Jan L. , Stan, Marius N. , Clarke, Bart L, Drake, Matthew T. , Shah, Mithun V , Clarke, B.L. , Bancos, Irina , Stan, Marius N

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | August 27, 2015 | Volume: 141 | Issue: 9 | Pages: 822

10.1001/jamaoto.2015.1497 | PMID 26312597 Get It

Abstract POSTER-BIOL-1327: Small cell carcinoma of the ovary, hypercalcemic type displays frequent inactivating germline and somatic mutations in SMARCA4
Craig, David W. , Sekulić, Aleksandar , Russell, Megan, Hendricks, William P.D. , Corneveaux, Jason J., Barrett, Michael T. , Shumansky, Karey, Yang, Yidong , Prentice, Leah , Kiefer, Jeffrey , Zismann, Victoria , Salhia, Bodour , Prat, Jaime, Farley, John , Anthony, Stephen P. , Cunliffe, Heather E. , Huntsman, David G. , Trent, Jeffrey M. , Ramos, Pilar , Karnezis, Anthony N. , Shah, Sohrab P. , Marra, Marco A. , McEachron, Troy A. , Clarke, Blaise , Pressey, Joseph G. , Roden, Richard

Mayo Clinic

Clinical Cancer Research | August 19, 2015 | Volume: 21 | Issue: 16_Supplement | Pages: POSTER-BIOL-1327-POSTER-BIOL-132

10.1158/1557-3265.ovcasymp14-poster-biol-1327 Get It

Abstract Introduction: Small cell carcinoma of the ovary of hypercalcemic type (SCCOHT) is arguably the most aggressive ovarian cancer. Most patients are diagnosed at an advanced stage, do not respond to chemotherapy, and die of disease within 1-2 years. It affects children and young women and is reported to occur in families. The cause of the disease is poorly understood. Therefore, we used next generation sequencing technology to identify the genetic basis of the disease. Method: We performed whole genome, whole exome sequencing or targeted sequencing on tumours and germline samples from 17 SCCOHT patients and on the SCCOHT cell line BIN-67 and SCCOHT-1. Immunohistochemistry (IHC) was performed on formalin-fixed, paraffin-embedded tumors from 23 patients and on a tissue microarray of 485 primary ovarian tumours of other subtypes. BIN-67 cells harbouring biallelic inactivation of SMARCA4 were transduced with a lentivirus expressing wild type SMARCA4. Result: We identified inactivating germline and somatic mutations in the SWI/SNF chromatin-remodeling gene SMARCA4 in 79% (11/14) of SCCOHT patients, 2 of whom bore germline mutations, and in both cell lines. SMARCA4 protein was lost in 87% (20/23) of SCCOHT tumours but in only 0.4% (2/485) of other primary ovarian tumours. Reintroduction of wild-type SMARCA4 into BIN-67 cells resulted in altered cell morphology and growth arrest. Conclusions: The mutation spectrum, IHC profile and cell culture phenotype implicate SMARCA4 as a critical tumour suppressor in SCCOHT pathogenesis. Citation Format: Pilar Ramos, Anthony N. Karnezis, David W. Craig, Aleksandar Sekulic, Megan L. Russell, William P.D. Hendricks, Jason J. Corneveaux, Michael T. Barrett, Karey Shumansky, Yidong Yang, Sohrab P. Shah, Leah M. Prentice, Marco A. Marra, Jeffrey Kiefer, Victoria L. Zismann, Troy A. McEachron, Bodour Salhia, Jaime Prat, Blaise A. Clarke, Joseph G. Pressey, John H. Farley, Stephen P. Anthony, Richard B.S. Roden, Heather E. Cunliffe, David G. Huntsman, Jeffrey M. Trent. Small cell carcinoma of the ovary, hypercalcemic type displays frequent inactivating germline and somatic mutations in SMARCA4 [abstract]. In: Proceedings of the 10th Biennial Ovarian Cancer Research Symposium; Sep 8-9, 2014; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2015;21(16 Suppl):Abstract nr POSTER-BIOL-1327.
Response to Letter Regarding Article “Impact of Annual Operator and Institutional Volume on Percutaneous Coronary Intervention Outcomes: A 5-Year United States Experience (2005–2009)”
Badheka, Apurva O., Patel, Nileshkumar, Grover, Peeyush , Singh, Vikas , Patel, Nilay , Arora, Shilpkumar , Chothani, Ankit , Mehta, Kathan , Deshmukh, Abhishek , Savani, Ghanshyambhai T., Patel, Achint , Panaich, Sidakpal , Shah, Neeraj , Brown, Michael, Mohamad, Tamam , Makkar, Raj , Schreiber, Theodore , Rihal, Charanjit S. , Cohen, Mauricio G. , Rathod, Ankit D. , Grines, Cindy L. , Rihal, Charanjit S. , Panaich, Sidakpal S , Cohen, Mauricio G

Mayo Clinic

Circulation | August 3, 2015 | Volume: 132 | Issue: 5 | Pages: No page available

10.1161/circulationaha.115.015221 | PMID 26240270 Get It

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans
Korecka, Magdalena , Figurski, Michal, Toledo, Jon B. , Blennow, Kaj , Waligórska, Teresa, Brylska, Magdalena, Fields, Leona, Shah, Nirali, Soares, Holly , Dean, Robert A., Vanderstichele, Hugo, Petersen, Ronald C. , Aisen, Paul , Saykin, Andrew J. , Weiner, Michael W. , Trojanowski, John Q. , Shaw, Leslie M. , Initiative, Alzheimer's Disease Neuroimaging, Kang, Ju‐Hee , Zetterberg, Henrik , Initiative, Alzheimer's Disease Neuroimaging, Saykin, Andrew J

Mayo Clinic

Alzheimer's & Dementia | July 17, 2015 | Volume: 11 | Issue: 7 | Pages: 772-791

10.1016/j.jalz.2015.05.003 | PMID 26194312 Get It

AbstractIntroductionWe describe Alzheimer's Disease Neuroimaging Initiative (ADNI) Biomarker Core progress including: the Biobank; cerebrospinal fluid (CSF) amyloid beta (Aβ1–42), t‐tau, and p‐tau181 analytical performance, definition of Alzheimer's disease (AD) profile for plaque, and tangle burden detection and increased risk for progression to AD; AD disease heterogeneity; progress in standardization; and new studies using ADNI biofluids.MethodsReview publications authored or coauthored by ADNI Biomarker core faculty and selected non‐ADNI studies to deepen the understanding and interpretation of CSF Aβ1–42, t‐tau, and p‐tau181 data.ResultsCSF AD biomarker measurements with the qualified AlzBio3 immunoassay detects neuropathologic AD hallmarks in preclinical and prodromal disease stages, based on CSF studies in non‐ADNI living subjects followed by the autopsy confirmation of AD. Collaboration across ADNI cores generated the temporal ordering model of AD biomarkers varying across individuals because of genetic/environmental factors that increase/decrease resilience to AD pathologies.DiscussionFurther studies will refine this model and enable the use of biomarkers studied in ADNI clinically and in disease‐modifying therapeutic trials.